A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib

Osimertinib was a third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) in 2015 for treatment of non-small cell lung cancer (NSCLC). Our study was to explore the adverse events (AEs) caused by...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Yanchao, Shu, Yamin, Zhu, Junru, Li, Feie, Li, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664039/
https://www.ncbi.nlm.nih.gov/pubmed/36380085
http://dx.doi.org/10.1038/s41598-022-23834-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664039/
https://www.ncbi.nlm.nih.gov/pubmed/36380085
http://dx.doi.org/10.1038/s41598-022-23834-1

Ejemplares similares